Clinical Trial Update: PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for PIQHASSO evaluating PQR309 and eribulin in metastatic breast cancer across phase 1 and phase 2 (completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)
• PQR309

Snippet

Sponsor: PIQUR Therapeutics AG | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED